Evidence map›Paper›PMID 37196647›Full record

ArticleBlood advances2023

Diffuse large B-cell lymphomas have spatially defined, tumor immune microenvironments revealed by high-parameter imaging.

Kyle T Wright, Jason L Weirather, Sizun Jiang, Katrina Z Kao, Yari Sigal, Anita Giobbie-Hurder, Margaret A Shipp, Scott J Rodig

Abstract read
In one paragraph

Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Spatial-Omics Methods and Applications.Methods in molecular biology (Clifton, N.J.) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kyle T WrightDepartment of Pathology, Brigham and Women's Hospital, Boston, MA.
Jason L WeiratherDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0003-0556-0616
Sizun JiangDepartment of Microbiology and Immunology, Stanford University, Palo Alto, CA.ORCID 0000-0001-6149-3142
Katrina Z KaoCenter for Immuno-oncology, Dana-Farber Cancer Institute, Boston, MA.
Yari SigalIonpath Inc, Palo Alto, CA.ORCID 0000-0001-9636-4164
Anita Giobbie-HurderDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0003-2496-7737
Margaret A ShippDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-3949-6897
Scott J RodigDepartment of Pathology, Brigham and Women's Hospital, Boston, MA.

Funding

VASCULAR, PULMONARY AND RENAL INJURYT32HL007627 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI GIMBRONE, MICHAEL A, MITCHELL, RICHARD N · 1985 to 2019
$12.7M
Defining Mechanisms of Viral Persistence in Situ at the Single-Cell LevelR01AI149672 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI ESTES, JACOB D · 2020 to 2024
$4.0M
Spatial-Temporal Dissection of Stratified Host Tissue Responses to Severe acute respiratory syndrome-related coronaviruses in situ to Understand Intra-host PathogenesisDP2AI171139 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Sizun Jiang · 2022 to 2026
$2.3M
NHLBI NIH HHS T32 HL007627NIAID NIH HHS DP2 AI171139NIAID NIH HHS R01 AI149672
6 · The paper itself

Abstract

Diffuse large B-cell lymphoma (DLBCL) not otherwise specified is the most common aggressive non-Hodgkin lymphoma and a biologically heterogeneous disease. Despite the development of effective immunotherapies, the organization of the DLBCL tumor-immune microenvironment (TIME) remains poorly understood.We interrogated the intact TIME of 51 de novo DLBCLs with triplicate sampling to characterize 337 995 tumor and immune cells using a 27-plex antibody panel that captured cell lineage, architectural, and functional markers. We spatially assigned individual cells, identified local cell neighborhoods, and established their topographical organization in situ. We found that the organization of local tumor and immune cells can be modeled by 6 composite cell neighborhood types (CNTs). Differential CNT representation divided cases into 3 aggregate TIME categories: immune-deficient, dendritic cell-enriched (DC-enriched), and macrophage-enriched (Mac-enriched). Cases with immune-deficient TIMEs have tumor cell-rich CNTs, in which the few infiltrating immune cells are enriched near CD31+ vessels, in keeping with limited immune activity. Cases with DC-enriched TIMEs selectively include tumor cell-poor/immune cell-rich CNTs with high numbers of CD11c+ DCs and antigen-experienced T cells also enriched near CD31+ vessels, in keeping with increased immune activity. Cases with Mac-enriched TIMEs selectively include tumor cell-poor/immune cell-rich CNTs with high numbers of CD163+ macrophages and CD8 T cells throughout the microenvironment, accompanied by increased IDO-1 and LAG-3 and decreased HLA-DR expression and genetic signatures in keeping with immune evasion. Our findings reveal that the heterogenous cellular components of DLBCL are not randomly distributed but organized into CNTs that define aggregate TIMEs with distinct cellular, spatial, and functional features.

Indexed as

Lymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinCD8-Positive T-LymphocytesDiagnostic ImagingHumansIndoleamine-Pyrrole 2,3,-DioxygenaseTumor MicroenvironmentIndoleamine-Pyrrole 2,3,-Dioxygenase

Identifiers

PMID37196647
PMCPMC10448427

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.